Pieris Pharmaceuticals GmbH
🇩🇪Germany
Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Phase 1
Completed
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Biological: PRS-080-Placebo#001Biological: PRS-080#022-DP
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 11
- Registration Number
- NCT03325621
- Locations
- 🇨🇿
HDS - Klaudian's Hospital, Mladá Boleslav, Czechia
🇨🇿VFN Strahov, Prague, Czechia
🇨🇿Institute of Clinical and Experimental Medicine (ICEM), Prague, Czechia
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Phase 1
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Biological: PRS-080#022-DPBiological: PRS-080-Placebo#001
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT02754167
- Locations
- 🇩🇪
Technical University, Medical Department, Munich, Germany
🇩🇪St. Joseph Krankenhaus, Berlin, Germany
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080
- First Posted Date
- 2015-01-16
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT02340572
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Drug: Angiocal® (PRS-050-PEG40)
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2011-10-19
- Lead Sponsor
- Pieris Pharmaceuticals GmbH
- Target Recruit Count
- 26
- Registration Number
- NCT01141257
© Copyright 2025. All Rights Reserved by MedPath